

## **Spectrum** Physician's Orders **Health** PAMIDRONATE (A **PAMIDRONATE (AREDIA) -**ADULT, OUTPATIENT, **INFUSION CENTER**

Page 1 to 3

Patient Name
DOB
MRN
Physician
FIN

Defaults for orders not other lands once lnterval: daily times 3 controls interval: everyc	doses (Paget's Disease)						
Duration:  ☐ Until date: ☐ 1 year ☐# of Treatments							
Anticipated Infusion Date_	ICD 10 Code with Des	cription					
Height(cm) Weight(kg) Allergies							
Provider Specialty							
☐ Allergy/Immunology	☐ Infectious Disease	□ OB/GYN	☐ Rheumatology				
☐ Cardiology	☐ Internal Med/Family Practice	☐ Other	☐ Surgery				
☐ Gastroenterology	☐ Nephrology	□ Otolaryngology	☐ Urology				
☐ Genetics	☐ Neurology	☐ Pulmonary	☐ Wound Care				
Site of Service							
☐ SH Gerber	☐ SH Lemmen Holton (GR)	□ SH Pennock	☐ SH United Memorial				
☐ SH Helen DeVos (GR)	☐ SH Ludington	□ SH Reed City	☐ SH Zeeland				
Infusion Appointme Status: Future, Expect Infusion  rovider Ordering Guidelines	ed: S, Expires: S+365, Sched. Tolerance: Sche	edule appointment at most 3 days	s before or at most 3 days after,				
ONC PROVIDER F PAMIDRONATE (ARE		F MALIGNANCY - EVEN IF PAT	IENT HAS RENAI				
INFUFFICIENCY	OSE WHEN GOING FOR THE EROALGEMIA O	I WALIONANOI - EVENII I AI	ILIVI HAO KLIVAL				
Infusion rate varies by preexisting renal insuff	indication. Longer infusion times (>2 hours) ma ficiency.	ay reduce the risk for renal toxicit	y, especially in patients with				
Hypercalcemia of mali Osteolytic bone lesion:	Infusion rates vary by diagnosis: Hypercalcemia of malignancy: Infuse over 2 to 24 hours Osteolytic bone lesions with metastatic breast cancer: Infuse over 2 hours						
· ·	Paget's disease: Infuse over 4 hours  Osteolytic bone lesions with multiple myeloma: Infuse over 4 hours						
•	ASCO guidelines for bisphosphonates use in multiple myeloma: Infuse over at least 2 hours						
	If therapy is withheld due to renal toxicity: Infuse over at least 4 hours upon reintroduction of treatment after renal recovery.						
Single dose should no	t exceed 90 mg.						
Frequency of therapy depends on indication and varies from a single dose to daily x 3 doses (Paget's Disease; total dose 90 mg), every 3 to 4 weeks, monthly and every 2 to 3 months.							
ursing Orders							

**ONC NURSING COMMUNICATION 100** May Initiate IV Catheter Patency Adult Protocol

## Spectrum PAMIDRONATE (AREDIA) Health ADULT, OUTPATIENT, INFUSION CENTER (CONTINUED)

Page 2 to 3

Patient Name
DOB
MRN
Physician
FIN

-1		
т	_	

Labs							
			Inte	erval		Dur	ration
_	<b>✓</b>	Comprehensive Metabolic Panel (CMP)		Every Once	_days		1 Treatment# of Treatments
	<b>✓</b>	Magnesium, Blood Level		Every Once	_days		1 Treatment # of Treatments
		Status: Future, Expected: S, Expires: S+365, URGENT, Clinic Collect	, Blo	-	enous		
	~	Phosphorus, Blood Level		Every Once	_days		1 Treatment # of Treatments
		Status: Future, Expected: S, Expires: S+365, URGENT, Clinic Collect	_	-	enous		n or modifications
	~	Alkaline Phosphatase, Blood Level		Every	_days		1 Treatment
		Status: Future, Expected: S, Expires: S+365, URGENT, Clinic Collect	Blo	Once od. Blood. Ve	enous		# of Treatments
	~	Vitamin D 25 Hydroxy		Every			1 Treatment
	Ľ	Vitaliiii B 20 Hydroxy	П	Once	_uuy5		# of Treatments
		Status: Future, Expected: S, Expires: S+365, URGENT, Clinic Collect	, Blo		enous		
	~	Calcitriol (1,25 Dihydroxyvitamin D), Serum		Every	_days		1 Treatment
				Once			# of Treatments
		Status: Future, Expected: S, Expires: S+365, URGENT, Clinic Collect	, Blo				
	<b>✓</b>	Creatinine, Urine Random		Every	_days		1 Treatment
		Status: Future, Expected: S, Expires: S+400, URGENT, Clinic Collect	 Urir	Once	an catch		# of Treatments
		Status. Future, Expected. C, Expires. C+400, State 141, Simile Concest	, 0111	ic, orine, or	an oaton		
		Lab:		Every	days		1 treatment
				Once			# of Treatments
Treati	ment	Parameters					
	~	ONC MONITORING AND HOLD PARAMETERS 3					
		May proceed with treatment if patient does not report any symptoms of	of jaw	or dental pa	ain.		
Vitals	<u> </u>						
		V() 10'					
	<b>✓</b>	Vital Signs	. :e.		41		an and as manded designs
		Routine, PRN, Starting S For Until specified, Vitals before pamidronal infusion per patient condition. Notify provider and stop drug infusion in					
		dyspnea, cough or bronchospasm.		, .	•	•	, 0, , 0
Medic	ation	ne					
Wiedic	atioi	13					
				_			
	<b>✓</b>	pamidronate (AREDIA) in sodium chloride 0.9 % 500 mL <b>Dose:</b>	IVF	РΒ			
		□ 30 mg					
		□ 60 mg					
		□ 90 mg					
		9					
		Base, Sodium Chloride 0.9%:					
		□ 250 mL (Bone metastases of breast cancer)					
		□ 500 mL (Paget's disease and bone metastases of	my	eloma)			
		□ 1000 mL (hypercalcemia)					
		Administer over:					
		2 hours					
		□ 4 hours					
		□ hours					

**Confidentiality of this medical record** shall be maintained except when use or disclosure is required or permitted by law, regulation, or written authorization by the patient.

Intravenous, Once, Starting S, For 1 Dose

## Spectrum PAMIDRONATE (AREDIA) - Health ADULT, OUTPATIENT, **ADULT, OUTPATIENT, INFUSION CENTER** (CONTINUED) Page 3 to 3

Patient Name
DOB
MRN
Physician
En.

	- \
- 1	
$\pm$	

## **Post-Infusion Labs**

Calcium, Blood Level, Total

Status: Normal, Expires: S+365, URGENT, Clinic Collect, Blood, Blood, Venous

**Confidentiality of this medical record** shall be maintained except when use or disclosure is required or permitted by law, regulation, or written authorization by the patient.

Telephone order/Verbal order documented and read-back completed. Practitioner's initials \_

NOTE: Unless Order is written DAW (dispense as written), medication may be supplied which is a generic equivalent by nonproprietary name.

TRANSCRIBED:		VALIDATED:		ORDERED:		
TIME	DATE	TIME	DATE	TIME	DATE	Pager #
	Sign		R.N. Sign		Physician Print	Physicia

EPIC VERSION DATE: 07/16/20